Covid Newscast

The Next-Generation Of Scientific Exploration And Research

Skip to content
  • Categories
    • Discovery
    • Clinical
    • Clinical Trials
    • Long Covid
    • Vaccines
    • Computing
    • Pandemic
    • Antibodies
  • Analytics
  • Resources
  • About Ingentium

Antibodies

Evidence related to Antibody research

  • Literature

  • Media

  • News

  • Antibodies Literature

    Anti-nucleocapsid and anti-spike antibody trajectories in people with post-covid condition versus acute-only infections: a nested longitudinal case-control study within the Virus Watch prospective cohort.

    April 19, 2025
    Publication date: Apr 17, 2025 People with Post-Covid Condition (PCC) may demonstrate aberrant immune responses ...
  • Antibodies Literature

    A Novel Antibody Against the Non-RBD Region of Middle East Respiratory Syndrome Coronavirus Spike Protein.

    April 19, 2025April 19, 2025
    Publication date: Apr 17, 2025 The Middle East respiratory syndrome coronavirus (MERS-CoV) was first identified ...
  • Antibodies Literature

    Persistent IgG1 clones dominate and personalize the plasma antibody repertoire.

    April 18, 2025
    Publication date: Apr 18, 2025 Antibodies play a pivotal role in the immune defense and ...
  • Antibodies Literature

    Impact of CD4+ T cell and TCR repertoires on SARS-CoV-2-Specific antibody responses in PLWH following COVID-19 vaccination.

    April 18, 2025April 18, 2025
    Publication date: Apr 15, 2025 In people living with human immunodeficiency virus (HIV, PLWH), the ...
  • Antibodies Literature

    Ferritin nanoparticle complex with porcine epidemic diarrhea virus spike protein induces neutralizing antibody response against PEDV in mouse models.

    April 12, 2025April 12, 2025
    Publication date: Jun 01, 2025 As the spike protein is the major antigen that contains ...
  • Antibodies Literature

    Autoantibodies neutralizing type I interferons remain a significant risk factor for critical COVID-19 pneumonia in vaccinated patients.

    April 8, 2025
    Publication date: Apr 02, 2025 Neutralizing autoantibodies against type I interferons were strongly linked to ...
  • Antibodies Literature

    Neutralizing antibody responses after a two-dose regimen with BNT162b2, CoronaVac or ChAdOx1-S in Brazil: Differential neutralization of SARS-CoV-2 omicron variants.

    April 8, 2025April 8, 2025
    Publication date: Apr 02, 2025 The emergence of SARS-CoV-2 variants has reduced antibody effectiveness, affecting ...
  • Antibodies Literature

    H3K27-me3 Inhibition Induces YTHDF2-Mediated Decay of m6A-Marked Severe Acute Respiratory Syndrome Coronavirus 2 Transcripts.

    April 7, 2025
    Publication date: Apr 01, 2025 Emerging evidence highlights the role of epigenetic modification in virus ...
  • Antibodies Literature

    Neutralizing antibodies to SARS-CoV-2 variants of concern: a pediatric surveillance study.

    April 7, 2025
    Publication date: Apr 04, 2025 Knowledge regarding the pediatric immune response to SARS-CoV-2 infection and/or ...
  • Antibodies Literature

    Development and validation of an LC-MS/MS method for pharmacokinetic assessment of a bispecific antibody (YBSW015) targeting SARS-CoV-2.

    April 7, 2025
    Publication date: Aug 01, 2025 YBSW015 is a bispecific antibody that targets severe acute respiratory ...
  • Antibodies Literature

    Rapid detection of systemic and mucosal antibody responses to COVID-19 infection or vaccination.

    April 7, 2025April 7, 2025
    Publication date: Apr 24, 2025 The presence of antibodies to SARS-Cov-2 spike protein in nasal ...
  • Antibodies Literature

    The effect of pre-existing coronavirus antibodies on SARS-CoV-2 infection outcomes in exposed household members.

    April 6, 2025
    Publication date: Apr 04, 2025 We investigated the effect of pre-existing antibodies against SARS-CoV-2 and ...
  • Antibodies Literature

    A global collaboration for systematic analysis of broad-ranging antibodies against the SARS-CoV-2 spike protein.

    April 6, 2025
    Publication date: Apr 02, 2025 The Coronavirus Immunotherapeutic Consortium (CoVIC) conducted side-by-side comparisons of over ...
  • Antibodies Literature

    Age-related peculiarities of antibody-mediated humoral immune response following SARS-CoV-2 infection.

    April 5, 2025April 5, 2025
    Publication date: May 01, 2025 Thousands of articles were published about the COVID-19 disease and ...
  • Antibodies Literature

    Monoclonal Antibodies for Pediatric Viral Disease Prevention and Treatment.

    April 4, 2025
    Publication date: Apr 03, 2025 Medical advancements over the last century have improved our ability ...
  • Antibodies Literature

    Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma.

    April 4, 2025
    Publication date: Mar 31, 2025 Bispecific antibodies (BsAb) are associated with distinct immune-related toxicities that ...
  • Antibodies Literature

    Non-neutralizing anti-type I interferon autoantibodies could increase thrombotic risk in critical COVID-19 patients.

    April 3, 2025
    Publication date: Jan 07, 2025 During the COVID-19 pandemic, approximately 15% of patients with severe ...
  • Antibodies Literature

    Antibodies against SARS-CoV-2 in cerebrospinal fluid: Clinical features and laboratory findings of hospitalized patients with neurologic symptoms in the pandemic era.

    April 2, 2025
    Publication date: Mar 30, 2025 High titers of anti-SARS-CoV-2 immunoglobulin G (IgG) have been reported ...
  • Antibodies Literature

    Virus-specific antibody responses in severe acute respiratory syndrome coronavirus 2-infected and vaccinated individuals.

    April 2, 2025April 2, 2025
    Publication date: Mar 27, 2025 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can have ...
  • Antibodies Literature

    Seroprevalence of SARS-CoV-2 antibodies in patients with hematological and oncological diseases in early 2024.

    March 30, 2025
    Publication date: Mar 28, 2025 COVID-19 remains a major threat to immunocompromised individuals. The determination ...
  • Antibodies Literature

    Multiple exposures to SARS-CoV-2 Spike enhance cross-reactive antibody-dependent cellular cytotoxicity against SARS-CoV-1.

    March 30, 2025March 30, 2025
    Publication date: Mar 22, 2025 Vaccination or infection by SARS-CoV-2 elicits a protective immune response ...

Posts navigation

Older posts
ingentium

Ingentium Inc.
Email: support@ingentium.com
© 2023 Ingentium, Inc.

Additional

  • Analytics
  • Contact Us
  • Terms of Service Agreement

Archives

  • April 2025
  • March 2025
  • February 2025
  • January 2025
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}